A bold vision
for genetic medicines

AIRNA is committed to delivering the promise of RNA editing to people with rare diseases and common conditions

The promise of RNA editing

mother and child

We are developing novel medicines with the potential to deliver functional cures for patients.

Learn about our therapeutic focus

A bold vision
for genetic medicines

AIRNA is committed to delivering the promise of RNA editing to people with rare diseases and common conditions

The promise of RNA editing

We are developing novel medicines with the potential to deliver functional cures for patients.

Learn about our therapeutic focus

Our transformative RNA editing therapeutics have the potential to deliver individual solutions at scale

Learn about our science

We value teamwork, resilience, excellence, human, and health

RNA editing opens a world of possibilities never seen before.

Thorsten Stafforst
Founder

Join us

Latest News

Press Releases

30 January 2025

AIRNA Appoints Matthew Hawryluk as Chief Business Officer

Cambridge, MA, USA and Tübingen, Germany, January 30, 2025 – AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a […]

Read

Press Releases

31 July 2024

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic

Cambridge, MA, USA and Tübingen, Germany, July 31, 2024 – AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the successful closing of an oversubscribed $60 million financing round, which brings the total Series A funding to $90 million. The financing was led by […]

Read